Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorThe Affiliated People's Hospital of Ningbo University
About this trial
The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with relapsed/refractory hematological malignancies.
Eligibility criteria
Qualifiers
Histological diagnosis of hematological malignancies (such as lymphoma, myeloma, leukemia) refractory to, or relapsing after standard therapy.
Positive expression of specific antigens.
Eastern Cooperative Oncology Group (ECOG) performance status of 0~2.
Serum bilirubin ≤ 35 μmol/L;
Disqualifiers
History of allergy to any of the drugs involved in the protocol.
Left ventricular ejection fraction (LVEF) < 50%;
Class III or IV heart failure as defined by the New York Heart Association (NYHA).
History of another malignancy tumor.
Trial design
Treatments tested in this trial
- Autologous CAR-T cells
- Fludarabine
- Cyclophosphamide
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
The Affiliated People's Hospital of Ningbo University
Lead sponsor
UTC Therapeutics Inc.
Collaborator
Source ClinicalTrials.gov